發(fā)布時間：2018-03-11 04:09

  本文選題：急性冠狀動脈綜合征　切入點：氯吡格雷　出處：《中國臨床藥理學(xué)雜志》2017年07期 　論文類型：期刊論文

【摘要】：目的觀察經(jīng)皮冠狀動脈介入治療(PCI)術(shù)后急性冠狀動脈綜合征(ACS)患者的細胞色素P450 2C19(CYP2C19)、PON1及ABCB1基因多態(tài)性與氯吡格雷抵抗的相關(guān)性。方法用熒光染色原位雜交方法檢測175例進行PCI的ACS患者的CYP2C19*2、*3、*17、PON1及ABCB1基因型,用血栓彈力圖法檢測血小板聚集率。將血小板聚集率50%的患者列入氯吡格雷抵抗組,血小板聚集率≤50%列入氯吡格雷敏感組。結(jié)果 CYP2C19*2、*3基因為突變雜合型,氯吡格雷抵抗發(fā)生率較野生型顯著升高,而CYP2C19*2/*2、*2/*3發(fā)生氯吡格雷抵抗的風(fēng)險更高。PON1基因突變率為59.43%,其中突變純合型為15.43%。ABCB1突變率為60.57%,其中突變純合型為14.86%。兩者雖然突變率較高,但都對氯吡格雷抵抗發(fā)生率沒有明顯影響。結(jié)論 PCI術(shù)后ACS患者的CYP2C19*2、*3基因突變顯著影響氯吡格雷療效,PON1及ABCB1基因則與其無顯著相關(guān)性。
[Abstract]:Objective to investigate the association between cytochrome P450 2C19 CYP2C19 CYP2C19 PON1 and ABCB1 gene polymorphisms and clopidogrel resistance in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods fluorescence staining in situ hybridization was used to detect the relationship between cytochrome P450 2C19 and CYP2C19 PON1 and clopidogrel resistance. The genotypes of CYP2C192C192O2P01 and ABCB1 were detected in 175 ACS patients with PCI. Patients with platelet aggregation rate (50%) were included in clopidogrel resistance group and platelet aggregation rate 鈮，

本文編號：1596496